NasdaqCM - Nasdaq Real Time Price USD

GlycoMimetics, Inc. (GLYC)

0.2402
-0.0023
(-0.95%)
At close: May 9 at 4:00:00 PM EDT
0.2500
+0.01
+(4.08%)
Pre-Market: 8:17:29 AM EDT
Loading Chart for GLYC
  • Previous Close 0.2425
  • Open 0.2507
  • Bid --
  • Ask 0.2444 x 300
  • Day's Range 0.2377 - 0.2557
  • 52 Week Range 0.1400 - 0.6300
  • Volume 143,665
  • Avg. Volume 1,459,945
  • Market Cap (intraday) 15.496M
  • Beta (5Y Monthly) 1.70
  • PE Ratio (TTM) --
  • EPS (TTM) -0.5900
  • Earnings Date May 8, 2025 - May 12, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

GlycoMimetics, Inc. engages in the discovery and development of therapies for cancers and inflammatory diseases in the United States. The company was founded in 2003 and is based in Monrovia, Maryland.

www.glycomimetics.com

4

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GLYC

View More

Performance Overview: GLYC

Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

GLYC
3.92%
S&P 500 (^GSPC)
3.77%

1-Year Return

GLYC
19.93%
S&P 500 (^GSPC)
8.55%

3-Year Return

GLYC
61.26%
S&P 500 (^GSPC)
41.81%

5-Year Return

GLYC
91.94%
S&P 500 (^GSPC)
93.18%

Compare To: GLYC

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GLYC

View More

Valuation Measures

Annual
As of 5/9/2025
  • Market Cap

    15.50M

  • Enterprise Value

    4.84M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.92

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -72.04%

  • Return on Equity (ttm)

    -173.25%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -37.88M

  • Diluted EPS (ttm)

    -0.5900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    10.72M

  • Total Debt/Equity (mrq)

    1.26%

  • Levered Free Cash Flow (ttm)

    -14.28M

Research Analysis: GLYC

View More

Company Insights: GLYC

Research Reports: GLYC

View More

People Also Watch